Dr. Christopher Cogle, M.D., discusses one of his active clinical trials, iCare for Cancer Patients, which was made possible with funding from the nonprofit Gateway for Cancer Research. This blood cancer trial involves precision medicine — tailoring treatment based on unique gene mutations, as only about 40 percent of blood cancer patients respond to standard chemotherapy. For more information about the trial including eligibility criteria, please click here.
Cogle is a professor of medicine in the UF College of Medicine, as well as a physician-scientist with clinical and research expertise in the myelodysplastic syndromes, acute leukemias and bone marrow failure syndromes.
